FDA approves Merck & Go heart attack and stroke drug

摘要

The FDA has approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with! a previous heart attack or: blockages in the arteries to the legs: Zontivity is the first in a new class of drug, a protease-activafed: receptor-1 (PAR-1) antagonist. It is an anti-platelet agent, designed to decrease the tendency of platelets to clump together to form a blood cloL'By decreasing the formation of blood clots, Zontivity decreases therisk of heart attackahd stroke.